semaglutide serious side effects GI Adverse of Glucagon-Like Peptide-1 Receptor Agonists New Side Effects of Semaglutide

Obesity Reviews : An Official Journal of the International Association for the Study of Obesity

Patients in whom ascites develops have a marked inability to excrete sodium

If you experience any suspected side effects from Rybelsus, even after stopping the medication, report them via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or the Yellow Card app)

Medical and regulatory references: FDA announcement on Foundayo/orforglipron approval JAMA report on FDA approval of oral orforglipron Novo Nordisk announcement on Wegovy pill approval and OASIS 4 results New England Journal of Medicine: Oral semaglutide 25 mg in adults with overweight or obesity JAMA Surgery: Obesity treatment with bariatric surgery vs GLP-1 receptor agonists NIDDK: Prescription medications to treat overweight and obesity ASMBS patient resources on metabolic and bariatric surgery